Drug setback leaves Ascletis with an all-in bet on weight loss
The company’s two core hepatitis drugs were dropped from China’s state insurance scheme on July 1, effectively wiping out the remains of its legacy drug sales Key Takeaways: The company…
Recent Articles
RELATED ARTICLES
-
BRIEF: Ascletis raises $107 million to fund obesity drug trials
1672.HK - Precision-drug maker Impact Therapeutics ignites IPO frenzy
- Jacobio Pharma poised to turn a profit from precision cancer drugs
- A healthy return: drug spin-off nets Keymed up to $320 million
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
- Big deal, bigger doubts: CSPC slides after $18.5 billion pact
-
Drug spin-off trend gains traction with IPO by Hengrui offshoot
1276.HK600276.SHG
